Lilly and Novo develop amylin drugs for obesity and diabetes
Eli Lilly and Novo are developing amylin drugs for treating obesity and diabetes, according to CNBC. The medicines represent an additional biological approach alongside GLP-1 treatments, but the supplied information does not specify their development stages, clinical results, regulatory status, or expected availability.
Eli Lilly and Novo are developing new amylin drugs aimed at treating obesity and diabetes, CNBC reported on October 2, 2026.
Amylin is described in the report as another biological lever for treatment. The supplied information does not identify the specific drug candidates, explain how they work, or state whether either company is testing an amylin medicine alone or in combination with another treatment.
The report does not provide clinical-trial results, patient numbers, efficacy or safety findings, regulatory decisions, projected launch dates, or financial details. It also does not specify whether the programs have reached human testing or describe how they compare with existing GLP-1 medicines.
Further details about the companies' development plans, trial timelines and potential next steps were not included in the supplied source excerpt.
THE QUESTIONS THIS EVENT LEAVES BEHIND
What evidence will determine whether amylin medicines offer benefits beyond existing GLP-1 treatments?
How might the companies' development timelines affect competition in obesity and diabetes medicines?
Which patients could be excluded from or included in future amylin trials?
What pricing and access conditions would shape the medicines' practical impact if they reach the market?
How could unsuccessful trials change the companies' strategies for combining biological treatment approaches?
YOUR QUESTION
Does this story leave you with another question?
Send us the question the report did not answer. It may become the next question IAQ investigates.
GLOBAL CURIOSITY MAP · SEPTEMBER 2026